更新于：2024-11-01

Perioperative hypertension

围手术期高血压

更新于：2024-11-01

基本信息

别名

Perioperative hypertension、Perioperative hypertension (disorder)

简介-

关联

项与围手术期高血压相关的药物

Clevidipine

丁酸氯维地平

靶点

L-type calcium channel

作用机制

L-type calcium channel阻滞剂

在研机构

四川科伦药业股份有限公司 [+6]

原研机构

The Medicines Company (Spain) SL

在研适应症

高血压 [+2]

非在研适应症

急性失代偿性心力衰竭 [+5]

最高研发阶段批准上市

首次获批国家/地区

美国

首次获批日期2008-08-01

项与围手术期高血压相关的临床试验

ChiCTR2400086576 / SuspendedN/AIIT

Efficacy of Dexmedetomidine nasal spray on Perioperative Hemodynamics in Patients with Hypertension Undergoing Major Noncardiac Surgery

开始日期2024-07-05

申办/合作机构-

NCT05812755 / Recruiting临床4期IIT

The Effects of Soluble Guanylyl Cyclase Stimulation on Perioperative Vascular Reactivity and Organ Injury in Cardiac Surgery

The goal of this mechanistic clinical trial is to learn about the effects of medications called soluble guanylyl cyclase stimulators on vascular function and markers of kidney and brain injury in patients having heart surgery. The main questions it aims to answer are:
1. Does soluble guanylyl cyclase stimulation improve blood vessel function compared to placebo?
2. Does soluble guanylyl cyclase stimulation decrease markers of kidney injury and brain injury compared to placebo?
Participants will be randomized to a soluble guanylyl cyclase stimulator called vericiguat or placebo, and researchers will compare vascular function and markers of brain and kidney injury to see if vericiguat improves vascular function and reduces markers of injury.
This will provide important information to determine the underlying reasons that patients have some kidney and brain function problems after having heart surgery.

开始日期2023-05-19

申办/合作机构

Vanderbilt University Medical Center

[+1]

ISRCTN18251692 / CompletedN/AIIT

Research on key technologies for perioperative risk management in elderly patients

开始日期2022-01-01

申办/合作机构

新疆维吾尔自治区人民医院

100 项与围手术期高血压相关的临床结果

登录后查看更多信息

100 项与围手术期高血压相关的转化医学

登录后查看更多信息

0 项与围手术期高血压相关的专利（医药）

登录后查看更多信息

206

项与围手术期高血压相关的文献（医药）

2024-09-01·Journal of Cardiothoracic and Vascular Anesthesia

Insights Into Perioperative Hypertension Management in Europe: Results From a Survey Endorsed by the European Association of Cardiothoracic Anaesthesiology and Intensive Care (EACTAIC)

Article

作者: Locatelli, Martina ; Marabotti, Alberto ; Brizzi, Giulia ; de Arroyabe, Blanca Martinez Lopez ; Sangalli, Fabio ; Bertini, Pietro ; D'Amora, Mauro ; Guarracino, Fabio ; Paternoster, Gianluca

OBJECTIVESPerioperative blood pressure control is crucial to ensure organ perfusion and avoid adverse events. However, no consensus on blood pressure targets is available. This study was designed to gain insights into current European perioperative hypertension management practices.DESIGNSurvey research.SETTINGOnline survey.PARTICIPANTSThe survey was administered to members of the European Association of Cardiothoracic Anaesthesiology and Intensive Care and distributed through the organization's social media.INTERVENTIONSA 22-item questionnaire on the approach to perioperative hypertension control and its pharmacological management.MEASUREMENTS AND MAIN RESULTSThe study included surveys completed between July 1 and October 30, 2023. In total, 339 participants completed the questionnaire; 70% were anesthesiologists, 17% were intensive care physicians, and 12% were cardiac surgeons.MAJOR FINDINGSMore than 50% of respondents declared dealing with perioperative hypertension in 20% to 50% of their surgeries, and most target the 120 to 140 mmHg systolic blood pressure (SBP) range during surgery. Respondents mostly rely on α-adrenoreceptor antagonists (29%), nitrates (23%), and calcium channel blockers (15%) to manage perioperative hypertension. Titratable control was the most appreciated attribute of intravenous antihypertensives. Antihypertensive treatment failure occurred in less than 20% of surgeries, and the highest risk of hypotensive episodes was perceived by participants to be when using nitroglycerin and nitroprusside.CONCLUSIONSPerioperative SBP targets above 140 mmHg are uncommon among respondents, who predominantly target SBP values between 120 and 140 mmHg. The choice of intravenous antihypertensives is based on their manageability and user experience, and titratable control is the most appreciated characteristic.

2024-04-01·Journal of Plastic, Reconstructive & Aesthetic Surgery

Prediction model for haematoma after tissue expander placement: A retrospective cohort study of 7080 cases over 20 years

Article

作者: Liu, Wei ; Dong, Chen ; Song, Yajuan ; Ma, Xianjie ; Tang, Yinke ; He, Qiang ; Yu, Zhou ; Zhang, Yu ; Du, Jing ; Chu, Feifei

Haematoma is an early complication of tissue expander placement and can lead to infection, capsule contracture and various complications, hindering successful reconstruction. However, no scientific models can accurately predict the risk of haematoma following tissue expansion. Therefore, this study aimed to develop and validate a prediction model for haematoma following tissue expander placement. The medical records of patients who underwent expander placement between 2001 and 2021 were obtained from the clinical database of the Department of Plastic Surgery at the Xijing Hospital. A total of 4579 consecutive patients with 7080 expanders and 179 expanded pocket haematomas were analysed. Multivariate logistic regression analysis identified adult age (P = 0.006), male sex (P < 0.001), scar reconstruction (P = 0.019), perioperative hypertension (P < 0.001), face and neck location (P = 0.002) and activated partial thromboplastin time above the normal range (P < 0.001) as risk factors for haematoma. Therefore, these were included in the prediction model, and a nomogram was constructed. The discrimination of the nomogram was robust (area under the curve: 0.78; 95% confidence interval: 0.72-0.83). Further, the prediction model had a strong fit (Hosmer-Lemeshow test, P = 0.066) and maintained similar discrimination after considering performance optimism (bootstrapped area under the curve: 0.79; 95% confidence interval: 0.73-0.84). This clinical prediction model was created using a generalisable dataset and can be utilised to obtain valid haematoma predictions after expander placement, assisting surgeons in implementing preventive measures or interventions to reduce the occurrence of haematoma.

2024-02-18·Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences

[Risk factors of perioperative hypertension in dental implant surgeries with bone augmentation].

Article

作者: Zhou, Yin ; Liu, Xiaoqiang

OBJECTIVETo investigate the characteristics and risk factors of perioperative hypertension during dental implant surgeries with bone augmentation.METHODSA retrospective cohort study was conducted. Seven hundred and twenty-eight cases underwent dental implant placement and bone augmentation in Peking University School and Hospital of Stomatology from September 2021 to August 2022 were recruited in this study according to the inclusion and exclusion criteria. They were divided into different groups according to the exposure factors which were gender, age, surgical time, and surgical approach. The correlation between perioperative hypertension and the exposure factors was analyzed.RESULTSThe average systolic blood pressure variability was 9.93%±6.63% (maximum 50.41%), the average diastolic blood pressure variability was 12.45%±8.79% (maximum 68.75%), and the average mean arterial pressure variability was 10.02%±6.61% (maximum 49.48%). The incidence rate of perioperative hypertension was 26.77%. Male, age ≥ 60 years, and surgical time > 60 minutes were risk factors for perioperative hypertension (P < 0.05), and the relative risks (95%CI) were 1.74 (1.21-2.50), 2.35 (1.54-3.58), and 1.65 (1.15-2.38), respectively. There was no significant difference in the incidence of perioperative hypertension among the guided bone regeneration, sinus floor elevation with transalveolar approach, and sinus floor elevation with lateral window approach (P>0.05). However, the risk factors varied according to bone augmentation approaches. For the patients underwent guided bone rege-neration, the risk factors for perioperative hypertension included male, age ≥ 60 years, and surgical time > 60 minutes (P < 0.05). For the patients underwent maxillary sinus lift with transalveolar approach, the risk factor for perioperative hypertension was age ≥60 years (P < 0.05). For the patients underwent maxillary sinus lift with lateral window approach, male, age ≥60 years, and surgical time >60 minutes were not risk factors for perioperative hypertension (P>0.05).CONCLUSIONThere was a certain risk of perioperative hypertension in oral implantation with bone augmentation. The influence of male, age ≥60 years and surgical time > 60 minutes on perioperative hypertension was related to the approach of bone augmentation.